Depression

A raft of insights provide hope for improved treatments.

Mind-altering drugs might provide relief for those who don’t respond to conventional therapies — but does the hype outweigh the hope?

Despite growing awareness that children and teenagers can get depressed, substantial gaps remain in diagnosis and treatment.

Is it time for obesity to be treated as a mental-health concern?

Science is only now uncovering the complex interaction between hormones, neurosteroids and mood disorders.

Despite its chequered past, deep-brain electrical stimulation is finally showing some signs of success.

Neurogenesis can halt depressive symptoms or prevent them from emerging. Harnessing this phenomenon could open up treatment options.

Disrupted sleep patterns affect mental health, and researchers now hope that repairing circadian rhythms could ease symptoms.

How artificial intelligence detects lowered mood, why depression is linked to heart-disease risk, and other highlights.

Menopausal depression takes a huge toll, but is underfunded and under-researched — that needs to change.

This case report describes a biomarker-driven closed-loop therapy for depression using implanted electrodes to continually sense brain activity and automatically trigger direct brain electrical stimulation in high-depression states.

This bi-ancestral genome-wide association study of major depressive disorder (MDD) identified 178 risk variants. The results advance understanding of the biology of MDD and hint at new treatment possibilities.

Depressive disorders are among the leading causes of global disease burden. In this Perspective, Fried et al. argue that limited progress in understanding, predicting and treating depression despite a wealth of empirical research stems from issues in the methodological and theoretical foundations of depression measurement.

This study investigated trajectories of depressive symptoms associated with several health conditions using a sample of over 19,000 older adults. The presence of depressive symptoms was associated with poor health prognosis and increased mortality.

The antidepressant response to psilocybin in individuals with treatment-resistant depression is distinct from escitalopram and depends on a global increase in brain network integration.